Amgen Inc. reported robust financial performance for the second quarter of 2026, posting revenue of USD 10.05 billion, which represents a 9.5 percent year-over-year increase. The company also delivered earnings per share of USD 6.29, significantly beating the consensus estimate of USD 5.62 by USD 0.67. This strong operational result underscores Amgen's ability to generate growth amidst a competitive landscape. Beyond financial metrics, Amgen achieved a significant clinical milestone with positive topline Phase 3 results for its drug candidate dazodalibep in moderate-to-severe systemic Sjogren's disease, announced on September 22, 2026. While the primary endpoint was met in the OASIZ 301 trial, further studies are required before a regulatory filing can be pursued. This progress is viewed as crucial for expanding Amgen's late-stage pipeline and offsetting potential risks from patent expirations. Analyst sentiment regarding Amgen remains mixed following these developments. Scotiabank raised its price target to USD 500.00 while maintaining an Outperform rating, citing the company's strong position. Conversely, HSBC downgraded Amgen to Hold and cut its target to USD 425.00, reflecting ongoing concerns about valuation and future competitive pressures despite the recent clinical success. Amgen's stock traded at EUR 372.83 on September 30, 2026, with a market capitalization of USD 228.6 billion. The company provided full-year EPS guidance between USD 22.30 and USD 23.50, which aligns closely with the current analyst consensus of USD 22.94. Investors are now weighing the value of these clinical milestones against the broader market's valuation concerns and the necessity for continued pipeline conversion to drive future revenue.